Table 1 Donor, recipient and transplant characteristics.
From: Outcomes of pediatric kidney re-transplantation: a single-center cohort study
Variables | 1KT ( n = 89) | ReKT | P-value | P-value | ||
|---|---|---|---|---|---|---|
1KT + (N = 26) | 2KT (N = 26) | 3KT (N = 5) | ReKT | 1–3KT | ||
Donor | ||||||
Age, years (IQR) | 33.0 (15.0, 45.0) | 39.0 (18.3, 51.0) | 47.0 (35.5, 54.3) | 51.0 (30.5, 59.5) | 0.518 | 0.013 |
Gender, female (%) | 39 (43.8) | 9 (34.6) | 3 (11.5) | 3 (60.0) | 0.017 | 0.003 |
BMI, kg/m2 | 23.1 ± 4.5 | 23.7 ± 2.8 | 25.5 ± 3.9 | 24.6 ± 2.5 | 0.261 | 0.071 |
Donor type, LD (%) | 15 (16.9) | 4 (15.4) | 5 (19.2) | 0 | 0.563 | 0.570 |
Comorbidity (%) | ||||||
Hypertension | 6 (6.7) | 3 (11.5) | 3 (11.5) | 1 (20.0) | 0.904 | 0.492 |
Diabetes mellitus | 1 (1.1) | 1 (3.8) | 0 | 0 | 0.491 | 0.856 |
Cause of death CVA (%) | 17 (19.1) | 3 (11.5) | 7 (26.9) | 1 (20.0) | 0.328 | 0.253 |
Recipient | ||||||
Age, years (IQR) | 11.0 (7.0, 14.5) | 11.0 (3.8, 13.3) | 20.5 (12.75, 27.5) | 21.0 (11.0, 32.0) | < 0.001 | < 0.001 |
Gender, female, (%) | 33 (37.1) | 9 (34.6) | 2 (40.0) | 0.971 | 0.962 | |
BMI, kg/m2 | 17.9 ± 3.9 | 17.5 ± 3.8 | 21.5 ± 4.8 | 21.6 ± 1.1 | 0.008 | < 0.001 |
ESRD | ||||||
Congenital | 24 (27.0) | 3 (11.5) | 0 | 0.932 | 0.533 | |
FSGS | 14 (15.7) | 4 (15.4) | 0 | |||
Cystic | 13 (14.6) | 4 (15.4) | 1 (20.0) | |||
Glomerulonephritis | 4 (4.5) | 2 (7.7) | 1 (20.0) | |||
Interstitial nephritis | 9 (10.1) | 4 (15.4) | 0 | |||
Other | 22 (24.7) | 7 (26.9) | 2 (40.0) | |||
Unknown | 3 (3.4) | 2 (7.7) | 1 (20.0) | |||
Comorbidity (%) | ||||||
Hypertension | 66 (74.2) | 15 (57.7) | 20 (76.9) | 4 (80.0) | 0.904 | 0.820 |
Time on dialysis, months (IQR) | 16.8 (9.5, 31.1) | 16.5 (8.6, 24.5) | 48.0 (23.2, 86.0) | 47.0 (22.8, 93.0) | < 0.001 | < 0.001 |
Time on waiting list, months (IQR) | 5.9 (2.4, 16.6) | 4.6 (2.1, 9.0) | 31.1 (5.4, 51.99 | 26.9 (1.2, 112.0) | 0.005 | 0.011 |
Transplant | ||||||
Donor-recipient BSA ratio | 1.80 ± 0.94 | 2.09 ± 1.03 | 1.34 ± 0.46 | 1.48 ± 0.65 | 0.011 | 0.069 |
CMV D + R- (%) | 31 (34.8) | 9 (34.6) | 3 (11.5) | 2 (40.0) | 0.083 | 0.227 |
HLA mismatch ≥ 2 (%) | 65 (73.0) | 15 (57.7) | 17 (65.4) | 3 (60.0) | 0.748 | 0.892 |
PRA positive (%) | 11 (12.4) | 5 (19.2) | 17 (65.4) | 4 (80.0) | < 0.001 | < 0.001 |
CIT, hours | 10.6 ± 5.4 | 9.6 ± 6.0 | 15.8 ± 9.3 | 15.5 ± 2.1 | 0.163 | 0.012 |
Total WIT, minutes | 35.0 ± 16.6 | 27.5 ± 14.4 | 38.9 ± 32.2 | 46.0 ± 11.3 | 0.374 | 0.636 |
Surgery time, minutes | 199.3 ± 56.8 | 218.3 ± 83.0 | 171.0 ± 56.3 | 387.3 ± 389.0 | 0.026 | < 0.001 |
Intraoperative complications, all (%) | 13 (14.6) | 5 (19.2) | 1 (3.8) | 0 | 0.051 | 0.210 |
Induction therapy | 13 (14.6) | 5 (19.2) | 14 (53.8) | 2 (40.0) | 0.021 | < 0.001 |
ATG/ ILR2-RA (%) | 0, 13 (100) | 0, 5 (100) | 1 (7.1), 13 (92.9) | 1 (50.0), 1 (50.0) | 0.309 | 0.102 |
Initial immunosuppression (%) | ||||||
CsA | 54 (60.7) | 22 (84.6) | 10 (38.5) | 3 (60.0) | 0.007 | 0.191 |
Tac | 33 (37.1) | 2 (7.7) | 15 (57.7) | 2 (40.0) | ||
Tac + Ever | 2 (2.2) | 0 | 3 (11.5) | 0 | ||
Aza | 2 (2.2) | 2 (7.7) | 0 | 0 | ||
Total follow-up, years (IQR) | 15.1 (6.9, 24.1) | 24.9 (18.6, 28.2) | 12.1 (3.4, 23.1) | 17.4 (12.7, 23.6) | < 0.001 | 0.502 |
